Association between BRAF V600E mutation and recurrence of papillary thyroid cancer

Mingzhao Xing, Ali S. Alzahrani, Kathryn A. Carson, Young Kee Shong, Tae Yong Kim, David Viola, Rossella Elisei, Bela Bendlová, Linwah Yip, Caterina Mian, Federica Vianello, R. Michael Tuttle, Eyal Robenshtok, James A. Fagin, Efisio Puxeddu, Laura Fugazzola, Agnieszka Czarniecka, Barbara Jarzab, Christine J. O'Neill, Mark S. SywakAlfred K. Lam, Garcilaso Riesco-Eizaguirre, Pilar Santisteban, Hirotaka Nakayama, Roderick Clifton-Bligh, Giovanni Tallini, Elizabeth H. Holt, Vlasta Sýkorová

Research output: Contribution to journalArticlepeer-review


Purpose: To investigate the prognostic value of BRAFV600E mutation for the recurrence of papillary thyroid cancer (PTC) Patients and Methods: This was a retrospective multicenter study of the relationship between BRAF V600E mutation and recurrence of PTC in 2,099 patients (1,615 women and 484 men), with a median age of 45 years (interquartile range [IQR], 34 to 58 years) and a median follow-up time of 36 months (IQR, 14 to 75 months) Results: The overall BRAF V600E mutation prevalence was 48.5% (1,017 of 2,099). PTC recurrence occurred in 20.9% (213 of 1,017) of BRAFV600E mutation-positive and 11.6% (125 of 1,082) of BRAFV600E mutation-negative patients. Recurrence rates were 47.71 (95% CI, 41.72 to 54.57) versus 26.03 (95% CI, 21.85 to 31.02) per 1,000 person-years in BRAF mutation-positive versus - Negative patients (P

Original languageEnglish
Pages (from-to)42-50
Number of pages9
JournalJournal of Clinical Oncology
Issue number1
Publication statusPublished - Jan 1 2015

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Association between BRAF V600E mutation and recurrence of papillary thyroid cancer'. Together they form a unique fingerprint.

Cite this